Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 28:10:507.
doi: 10.12688/f1000research.28327.2. eCollection 2021.

Novel antifungal agents in clinical trials

Samantha E Jacobs  1 , Panagiotis Zagaliotis  2 , Thomas J Walsh  2   3
Affiliations
Review

Novel antifungal agents in clinical trials

Samantha E Jacobs et al. F1000Res. .

Abstract

Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.

Keywords: Antifungal Agents; clinical trials; novel treatments; pharmacokinetic and pharmacodynamic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: TJW has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, Tetraphase, and Viosera; and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis. SEJ and PZ declare no competing interests.

References

    1. Brown GD, Denning DW, Gow NAR, et al. : Hidden killers: Human fungal infections. Sci Transl Med. 2012;4(165):165rv13. 10.1126/scitranslmed.3004404 - DOI - PubMed
    1. Miyazaki M, Horii T, Hata K, et al. : In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652–4658. 10.1128/AAC.00291-11 - DOI - PMC - PubMed
    1. Pfaller MA, Huband MD, Flamm RK, et al. : In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017. Antimicrob Agents Chemother. 2019;63(8): e00840-19. 10.1128/AAC.00840-19 - DOI - PMC - PubMed
    1. Wiederhold NP, Najvar LK, Fothergill AW, et al. : The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans. Antimicrob Agents Chemother. 2015;59(1):690–692. 10.1128/AAC.03944-14 - DOI - PMC - PubMed
    1. Hager CL, Larkin EL, Long L, et al. : In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62(3): e02319-17. 10.1128/AAC.02319-17 - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources